A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03A in First Line Metastatic Participants
Renal cell carcinoma is the most common form of kidney cancer. When it spreads to other areas of the body, doctors call it advanced or metastatic cancer. This clinical trial is testing whether combining immunotherapy medicines with targeted cancer drugs can treat it more effectively. Immunotherapy helps your body's own immune system find and attack cancer cells. Targeted drugs work by blocking specific signals that cancer cells need to grow and survive. In this trial, researchers are testing medicines such as pembrolizumab and lenvatinib alongside newer experimental drugs. The study is for adults who have not yet had medication for their advanced kidney cancer. Doctors want to find out which drug combinations are safest, what side effects they cause, and how well they shrink or control tumours over time.
At a glance
What is this study about?
Kidney cancer usually starts in the tiny tubes inside the kidneys. The most common type is called renal cell carcinoma. In some cases, the cancer spreads beyond the kidney to other parts of the body, such as the lungs or bones. When this happens, doctors need treatments that work throughout the whole body rather than surgery alone.
This study, called KEYMAKER-U03, is looking at new combinations of medicines for people who are starting treatment for advanced kidney cancer for the first time. The trial combines two main types of treatment: immunotherapy and targeted therapy. Immunotherapy encourages your natural immune defences to fight cancer cells, while targeted therapies block the blood supply or growth signals that tumours rely on. Researchers believe that using these treatments together may be more powerful than using a single drug on its own.
The trial is taking place in two connected stages. The first part checks that the chosen doses are safe and well-tolerated. The second part looks closely at how well the combinations work to shrink tumours and keep the cancer from growing. By joining this trial, patients help doctors learn whether these modern combinations can offer better results and longer survival for people living with kidney cancer.
Key takeaways
- Tests new drug combinations for adults with advanced kidney cancer.
- Combines immunotherapy with targeted cancer therapies.
- Aimed at people who have not yet started drug treatment for advanced cancer.
- Checks drug safety, tolerable doses, and tumour shrinkage.
- Requires regular clinic visits for infusions, checks, and scans.
- Taking part is completely voluntary and you can withdraw at any time.
Who may be eligible?
This trial is open to men and women aged 18 and over who have been diagnosed with advanced or metastatic renal cell carcinoma (kidney cancer). To be eligible, you must be looking for your first main treatment for this stage of cancer, meaning you have not yet received regular drug treatment for cancer that has spread.
Your general health needs to be stable enough for you to take part safely. The study team will check that your heart, liver, and remaining kidney function are working well enough to process the trial medicines.
You may not be able to join if you have an active autoimmune condition, a serious uncontrolled illness, or if you have recently had certain other cancer therapies. Your oncology team will look at your full medical history and recent scan results to confirm whether this study is suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with renal cell carcinoma (kidney cancer).
- My cancer has spread or is considered advanced.
- I have not yet started medical drug treatment for advanced cancer.
- I am well enough to attend regular hospital appointments and scans.
What does participation involve?
Taking part begins with screening checks, including blood tests, physical examinations, and body scans (such as CT or MRI scans). If you join, you will be assigned to a specific combination of trial medicines. Some treatments are given as a drip into a vein at the hospital clinic every few weeks, while others are taken as daily tablets at home. You will have regular hospital visits so the doctors can monitor your blood pressure, check your blood results, and ask about any symptoms. You will also have scheduled scans every few months to see how your tumour is responding. Treatment continues for as long as it is helping you and side effects remain manageable, which can be several months or longer. After treatment finishes, the team will stay in touch to check on your overall health.
Potential risks and benefits
Locations (5)
- —UnverifiedHungary
- —UnverifiedSpain
- —UnverifiedNetherlands
- —UnverifiedPoland
- —UnverifiedFrance
Common questions
What is the difference between immunotherapy and targeted therapy?
Immunotherapy trains your body's own immune system to recognise and fight cancer cells. Targeted therapy attacks specific proteins or blood vessels that the cancer cells need to grow.
Will I receive a dummy treatment (placebo)?
No, this trial does not use a dummy pill on its own. All participants receive active cancer treatments designed to treat their condition.
Do I have to pay to take part in this trial?
No. The trial medicines and tests are provided free of charge, and some travel expenses to the hospital may be covered.
What happens if I experience unpleasant side effects?
You should tell your study team straight away. They can pause your treatment, adjust your doses, or give you medicines to help relieve your symptoms.
Can I leave the study if I change my mind?
Yes. You can leave the trial at any time without giving a reason. Your doctors will then discuss other standard care options with you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.